GlassScriptPhysician profile
Amelia Grace Damse
NPI 1346546587
$6,291.58
in general payments reported to CMS, 2019-2025
35 companies · $1,827 in 2025
The $1,827 reported for 2025 was more than what 87% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $127 · 2021: $652 · 2022: $414 · 2023: $673 · 2024: $1,496 · 2025: $1,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,956 · Education: $39.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,955.78 |
| Education | $39.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,180.80 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $738.17 | 2019-2025 | Tremfya, Remicade, Simponi |
| Organogenesis INC. | $568.39 | 2020-2025 | Nushield, Via Matrix, Affinity |
| Novartis Pharmaceuticals Corporation | $527.01 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $478.64 | 2019-2025 | Dupixent, Libtayo |
| Revance Therapeutics, INC. | $285.78 | 2024-2025 | Daxxify |
| Lilly USA, LLC | $255.53 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $255.50 | 2023-2025 | |
| Amgen INC. | $250.94 | 2021-2023 | Otezla, Repatha |
| Pfizer INC. | $186.13 | 2022-2025 | |
| Leo Pharma INC. | $153.47 | 2022-2024 | Adbry |
| Hill Dermaceuticals, INC. | $147.50 | 2025 | Tolak |
| E.R. Squibb & Sons, L.L.C. | $144.07 | 2024 | Sotyktu |
| Merz North America, INC. | $143.60 | 2020-2025 | Xeomin |
| Galderma Laboratories, L.P. | $104.40 | 2019-2023 | Aklief, Epsolay |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $97.33 | 2019 | |
| Biofrontera INC. | $97.14 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.34 | 2019 | |
| Ucb, INC. | $61.82 | 2023-2025 | Bimzelx, Cimzia |
| Amarin Pharma, INC. | $61.27 | 2021 | |
| Misonix INC | $61.17 | 2021 | |
| Sun Pharmaceutical Industries INC. | $60.19 | 2023-2025 | Ilumya |
| Smith+Nephew, INC. | $57.04 | 2023 | Grafix Pl, Collagenase Santyl |
| Journey Medical Corporation | $40.27 | 2023 | |
| Genentech USA, INC. | $38.71 | 2021-2024 | Erivedge |
| Novo Nordisk INC | $37.59 | 2021-2022 | |
| Mimedx Group, INC. | $30.28 | 2025 | |
| Alexion Pharmaceuticals, INC. | $26.35 | 2021 | |
| Incyte Corporation | $20.46 | 2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $19.75 | 2024 | Zoryve |
| Acera Surgical, INC. | $18.72 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $17.71 | 2023 | |
| Glaxosmithkline, LLC. | $17.26 | 2022 | |
| Kerecis Limited | $15.87 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Damse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.